Literature DB >> 30327352

ClonoSEQ Cleared for Residual Cancer Testing.

.   

Abstract

The FDA granted marketing authorization to the first-ever next-generation sequencing assay for detecting minimal residual disease in patients with acute lymphoblastic leukemia or multiple myeloma. ©2018 American Association for Cancer Research.

Entities:  

Year:  2018        PMID： 30327352     DOI： 10.1158/2159-8290.CD-NB2018-136

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  5 in total

1.  Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.

Authors:  Peter M Voorhees; Jonathan L Kaufman; Jacob Laubach; Douglas W Sborov; Brandi Reeves; Cesar Rodriguez; Ajai Chari; Rebecca Silbermann; Luciano J Costa; Larry D Anderson; Nitya Nathwani; Nina Shah; Yvonne A Efebera; Sarah A Holstein; Caitlin Costello; Andrzej Jakubowiak; Tanya M Wildes; Robert Z Orlowski; Kenneth H Shain; Andrew J Cowan; Sean Murphy; Yana Lutska; Huiling Pei; Jon Ukropec; Jessica Vermeulen; Carla de Boer; Daniela Hoehn; Thomas S Lin; Paul G Richardson
Journal:  Blood       Date:  2020-08-20       Impact factor: 22.113

2.  Navigating the nexus of MRD and novel agents in ALL.

Authors:  Anjali S Advani; Edward A Copelan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

3.  An Allogeneic Multiple Myeloma GM-CSF-Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission.

Authors:  Luca Biavati; Carol Ann Huff; Anna Ferguson; Amy Sidorski; M Amanda Stevens; Lakshmi Rudraraju; Cristina Zucchinetti; Syed Abbas Ali; Philip Imus; Christian B Gocke; Rachel M Gittelman; Sarah Johnson; Catherine Sanders; Marissa Vignali; Anita Gandhi; Xiaobu Ye; Kimberly A Noonan; Ivan Borrello
Journal:  Clin Cancer Res       Date:  2021-10-19       Impact factor: 13.801

4.  Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.

Authors:  Nirali N Shah; Daniel W Lee; Bonnie Yates; Constance M Yuan; Haneen Shalabi; Staci Martin; Pamela L Wolters; Seth M Steinberg; Eva H Baker; Cindy P Delbrook; Maryalice Stetler-Stevenson; Terry J Fry; David F Stroncek; Crystal L Mackall
Journal:  J Clin Oncol       Date:  2021-03-25       Impact factor: 44.544

Review 5.  Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy.

Authors:  Audrey M Sigmund; Kieran D Sahasrabudhe; Bhavana Bhatnagar
Journal:  Blood Lymphat Cancer       Date:  2020-11-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.